Qiagen (NASDAQ:QGEN) updated its fourth quarter 2018 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $0.39-0.40 for the period, compared to the Thomson Reuters consensus estimate of $0.42. The company issued revenue guidance of $420.714-424.683 million, compared to the consensus revenue estimate of $419.23 million.Qiagen also updated its FY 2018 guidance to $1.33-1.34 EPS.
Several analysts have commented on the stock. Commerzbank reaffirmed a buy rating on shares of Qiagen in a research note on Wednesday, July 25th. BidaskClub cut shares of Qiagen from a hold rating to a sell rating in a research note on Thursday, September 13th. Citigroup lifted their target price on shares of Qiagen from $35.00 to $38.00 and gave the stock a neutral rating in a research note on Thursday, August 2nd. Barclays reaffirmed a buy rating on shares of Qiagen in a research note on Tuesday. Finally, Morgan Stanley lifted their target price on shares of Qiagen from $37.00 to $38.00 and gave the stock an overweight rating in a research note on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $38.88.
QGEN stock traded up $0.88 during midday trading on Wednesday, hitting $36.44. The stock had a trading volume of 29,630 shares, compared to its average volume of 991,747. The company has a quick ratio of 4.59, a current ratio of 5.07 and a debt-to-equity ratio of 0.69. Qiagen has a 12-month low of $30.20 and a 12-month high of $39.45.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.